Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received an average rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $86.1429.

A number of brokerages have recently issued reports on LNTH. William Blair reiterated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Citizens Jmp boosted their price target on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 24th. Wall Street Zen upgraded shares of Lantheus from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 28th. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Mizuho boosted their price target on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th.

Lantheus Price Performance

Lantheus stock opened at $80.03 on Thursday. The stock has a market cap of $5.21 billion, a P/E ratio of 23.75 and a beta of -0.12. The company has a fifty day simple moving average of $74.04 and a 200-day simple moving average of $64.68. Lantheus has a 12-month low of $47.25 and a 12-month high of $108.91. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. The business had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.

Institutional Trading of Lantheus

A number of institutional investors have recently added to or reduced their stakes in LNTH. Hantz Financial Services Inc. boosted its holdings in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares in the last quarter. First Horizon Corp purchased a new stake in Lantheus during the third quarter worth about $26,000. Smartleaf Asset Management LLC boosted its holdings in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new stake in Lantheus during the second quarter worth about $36,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.